Iqvia (IQV) Stock
Global provider of clinical research services and extensive data. Here's the price, business snapshot, and what's worth knowing about Iqvia in June 2026.
IQVIA Holdings Inc. (IQV) is a global provider of clinical research services, real-world data, and analytics to the life sciences industry. It operates as a contract research organisation (CRO) delivering clinical trial management, regulatory support and commercial analytics, combining operational trial capabilities with large proprietary healthcare datasets and technology platforms. The business benefits from structural trends: pharmaceutical and biotech firms outsourcing R&D, rising demand for real-world evidence and use of analytics/AI to shorten time-to-market. With a market capitalisation around $37.2bn, IQVIA’s scale and global footprint are competitive advantages, though growth depends on contract wins, regulatory trends and continued tech investment. Key risks include competitive pressure, project concentration, regulatory and data-privacy challenges, and sensitivity to R&D budgets. This summary is for general educational purposes only and not personal investment advice; values can fall as well as rise and investors should check current filings and suitability for their circumstances.
Why It’s Moving
IQV Stock Surges on Analyst Hype as Strong Buy Ratings and AI-Driven Growth Fuel +45% Upside Expectations for 2026
- A broad consensus of over 25 Wall Street analysts has issued Strong Buy or Buy ratings, reflecting confidence in the company's ability to capitalize on steady revenue growth and improving earnings visibility.
- Investors are reacting positively to the company's strategic execution in R&D Solutions, where AI-driven demand is signaling stronger future performance and expanding market share.
- The broader pharmaceutical and biotech sector trend shows heightened investor appetite for firms with diversified commercial solutions, positioning IQV as a leader in an undervalued market segment.
IQV Stock Surges on Analyst Hype as Strong Buy Ratings and AI-Driven Growth Fuel +45% Upside Expectations for 2026
- A broad consensus of over 25 Wall Street analysts has issued Strong Buy or Buy ratings, reflecting confidence in the company's ability to capitalize on steady revenue growth and improving earnings visibility.
- Investors are reacting positively to the company's strategic execution in R&D Solutions, where AI-driven demand is signaling stronger future performance and expanding market share.
- The broader pharmaceutical and biotech sector trend shows heightened investor appetite for firms with diversified commercial solutions, positioning IQV as a leader in an undervalued market segment.
When is the next earnings date for IQVIA HOLDINGS INC (IQV)?
IQVIA Holdings is expected to report its next earnings on July 28, 2026, covering the second quarter of fiscal year 2026. This date aligns with the company's typical historical reporting schedule for its Q2 results, though the company has not formally confirmed the specific day yet. Investors should anticipate the announcement to occur before the market opens, consistent with the firm's previous earnings release practices. No financial advice or price targets are provided in this update.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IQVIA's stock with a target price of $254.95, indicating significant growth potential.
Financial Health
IQVIA is generating strong revenue and cash flow, indicating solid financial stability and growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring IQV
U.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketLife Sciences Brazil | Clinical Trial Stock Exposure
Brazil's expanding role in global medical research may increase local access to cutting-edge treatments and stimulate economic growth. This basket provides exposure to the theme through US and EU-listed companies that supply critical services and infrastructure for clinical trials in the region.
Published: 3 November 2025
Explore BasketClinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: 19 August 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: 5 August 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Research Demand
Outsourcing of drug development supports recurring project flow and long contract cycles, though revenues can vary with client R&D budgets and competitive pressures.
Global Footprint
A wide international presence helps win multinational trials and diversify revenues, but exposes the company to regulatory and currency headwinds.
Data and Analytics
Proprietary datasets and analytics platforms are differentiators as life sciences firms seek real‑world evidence and AI‑driven insights, though data governance is an ongoing risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
